Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Prostatic Neoplasms 4Lymphoma 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Colonic Neoplasms 2Burkitt Lymphoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Nose Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Metastatic Solid Tumors 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Liver Neoplasms 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Esthesioneuroblastoma, Olfactory 1Esophageal Neoplasms 1Epstein-Barr Virus Infections 1

Interventions

Specimen Handling 11Magnetic Resonance Spectroscopy 10pembrolizumab 4sacituzumab govitecan 3cabozantinib 3atezolizumab 3Taxes 3Paclitaxel 3Nivolumab 3Gemcitabine 3Biopsy 3eribulin 2erdafitinib 2Radiosurgery 2Platinum 2Ipilimumab 2Docetaxel 2Cisplatin 2Carboplatin 2CTLA-4 Antigen 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1tazemetostat 1sapanisertib 1olaparib 1enfortumab vedotin 1carotuximab 1Tomography, X-Ray Computed 1Suramin 1Panvac-VF 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Transitional Cell × Tomography, X-Ray Computed × Clear all
NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
45 enrolled 30 charts
GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡